REGENXBIO Doses First Patient in Phase IIb/III NAAVIGATE Trial for One-Time Gene Therapy in Diabetic Retinopathy, Receives $100 Million Milestone 1
REGENXBIO Announces Major Milestone: First Patient Dosed in ...
Sign in to continue:
REGENXBIO Announces Major Milestone: First Patient Dosed in ...
Nam Cheong Limited Incorporates New Subsidiary in UAE: Strat...
Zymeworks to Acquire Theravance Biopharma in \$929 Million D...
Barrel Energy Inc. Files Corrective Amendment on Series A Pr...
CIM Real Estate Finance Trust (CMFT) Acquires CIM Group, LLC...
Martin Marietta to Combine with Lhoist North America in \$13...
Vibrant Group Limited (SGX): FY2026 Financial Results Analys...
Halliburton 8-K Filing – Director Death Announcement Hal...
CDL Hospitality Trusts: Scheduled Release of H1 2026 Financi...
PEDEVCO Corp. Files 8-K: Chief Accounting Officer Paul Pinks...